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Salvia miltiorrhiza treatment during early
reperfusion reduced postischemic myocardial
injury in the rat
Ruqiong Nie, Rui Xia, Xingwu Zhong, and Zhengyuan Xia
Abstract: Oxidative stress may play a causative role in myocardial ischemia–reperfusion injury. However, it is a relatively
understudied aspect regarding an optimal timing of antioxidant intervention during ischemia–reperfusion. The present study
investigates the effect of different treatment regimens of Salvia miltiorrhiza (SM) herb extracts containing phenolic com-
pounds that possess potent antioxidant properties on postischemic myocardial functional recovery in the setting of global
myocardial ischemia and reperfusion. Langendorff-perfused rat hearts were subjected to 40 min of global ischemia at
37 8C followed by 60 min of reperfusion, and were randomly assigned into the untreated control and 2 SM-treated groups
(n = 7 per group). In treatment 1 (SM1), 3 mg/mL of water soluble extract of SM was given for 10 min before ischemia
and continued during ischemia through the aorta at a reduced flow rate of 60 mL/min, but not during reperfusion. In treat-
ment 2 (SM2), SM (3 mg/mL) was given during the first 15 min of reperfusion. During ischemia, hearts in the control and
SM2 groups were given physiological saline at 60 mL/min. The SM1 treatment reduced the production of 15-F2t-isoprostane,
a specific index of oxidative stress-induced lipid peroxidation, during ischemia (94 ± 20, 43 ± 6, and 95 ± 15 pg/mL
in the coronary effluent in control, SM1, and SM2 groups, respectively; p < 0.05, SM1 vs. control or SM2) and post-
poned the onset of ischemic contracture. However, SM2, but not the SM1 regimen, significantly reduced 15-F2t-isoprostane
production during early reperfusion and led to optimal postischemic myocardial functional recovery (left ventricular
developed pressure 51 ± 4, 46 ± 4, and 60 ± 6 mmHg in the control, SM1, and SM2 groups, respectively, at 60 min
of reperfusion; p < 0.05, SM2 vs. control or SM1) and reduced myocardial infarct size as measured by triphenyltetra-
zolium chloride staining (26% ± 2%, 22% ± 2%, and 20% ± 2% of the total area in the control, SM1, and SM2
groups, respectively, p < 0.05, SM2 vs. control). It is concluded that S. miltiorrhiza could be beneficial in the treat-
ment of myocardial ischemic injury and the timing of administration seems important.
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Re´sume´ : Le stress oxydatif pourrait eˆtre un facteur de´terminant dans la le´sion d’ische´mie-reperfusion myocardique. Tou-
tefois, cet aspect est relativement ne´glige´ en ce qui touche le moment optimal de l’intervention antioxydante durant
l’ische´mie-reperfusion. La pre´sente e´tude examine l’effet de diffe´rents sche´mas de traitement avec des extraits de Salvia
miltiorrhiza (SM), qui contiennent des compose´s phe´noliques dote´s de puissantes proprie´te´s antioxydantes, sur le re´tablis-
sement de la fonction myocardique post-ische´mique dans le contexte d’une ische´mie myocardique globale suivie d’une re-
perfusion. Des cœurs de rats perfuse´s selon la me´thode de Langendorff ont e´te´ soumis a` une ische´mie globale a` 37 8C
durant 40 min et a` une reperfusion durant 60 min, puis ont e´te´ re´partis ale´atoirement dans le groupe te´moin non traite´ et
dans deux groupes traite´s avec SM (n = 7 par groupe). Dans le traitement 1 (SM1), 3 mg/mL d’extrait aqueux soluble de
SM ont e´te´ administre´s pendant 10 min avant et durant l’ische´mie a` travers l’aorte, a` raison de 60 mL/min, mais pas durant
la reperfusion. Dans le traitement 2 (SM2), SM (3 mg/mL) a e´te´ a e´te´ administre´ durant les premie`res 15 min de la reper-
fusion. Durant l’ische´mie, les cœurs des groupes te´moin et SM2 ont e´te´ perfuse´s avec une solution saline, a` raison de
60 mL/min. Le traitement SM1 a re´duit la production de 15-F2t-isoprostane, un indice spe´cifique de la peroxydation lipi-
dique induite par le stress oxydatif, durant l’ische´mie (94 ± 20 pg/mL, 43 ± 6 pg/mL et 95 ± 15 pg/mL dans l’effluent co-
ronaire des groupes te´moin, SM1 et SM2, respectivement; p < 0,05, SM1 vs te´moin ou SM2) et retarde´ le de´but de la
contracture ische´mique. Toutefois, le traitement SM2, mais pas de SM1, a re´duit significativement la production de 15-F2t-
isoprostane durant la reperfusion pre´coce, et conduit a` un re´tablissement optimal de la fonction myocardique post-
ische´mique (pression de´veloppe´e ventriculaire gauche : 51 ± 4 mmHg, 46 ± 4 mmHg et 60 ±6 mmHg chez les groupes te´-
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moin, SM1 et SM2, respectivement, apre`s 60 min de reperfusion; p < 0,05, SM2 vs te´moin ou SM1) et re´duit la taille de
l’infarctus du myocarde, comme mesure´ par la coloration avec le chlorure de triphe´nylte´trazolium (26 ± 2 %, 22 ± 2 % et
20 ± 2 % de la surface totale chez les groupes te´moin, SM1 et SM2, respectivement; p < 0,05, SM2 vs te´moin). On
conclut que S. miltiorrhiza pourrait eˆtre be´ne´fique dans le traitement de la le´sion ische´mique myocardique et que le mo-
ment de l’administration serait important.
Mots-cle´s : Salvia miltiorrhiza, ische´mie-reperfusion du myocarde, 15-F2t-isoprostane.
[Traduit par la Re´daction]
______________________________________________________________________________________
Introduction
Salvia miltiorrhiza (SM, also known as danshen or
tanshen) is a plant that has been used extensively as a tradi-
tional medicine for treating cardiovascular diseases in China
and Japan. The aqueous extract of SM contains mainly phe-
nolic compounds such as salvianolic acid A and B, rosmar-
inic acid, and 3,4-dihydroxyphenyl lactate (danshensu)
(Fig. 1) (Zhou et al. 2005), which have been shown to pos-
sess potent free-radical scavenging properties (Liu et al.
1992; Zhou and Ruigrok 1990). The administration of water
soluble extraction of SM has been found to reduce the size
of myocardial infarction induced by ischemia and reperfu-
sion in both isolated and intact rabbit hearts (Wu et al.
1993; Fung et al. 1993). Water soluble extraction of SM
was also found to increase the recovery of left ventricular
developed pressure and attenuate the elevation in end-
diastolic pressure during the postischemic reperfusion of
isolated rat hearts (Zhou and Ruigrok 1990; Yagi et al.
1989). However, in these studies (Wu et al. 1993; Fung et
al. 1993; Zhou and Ruigrok 1990; Yagi et al. 1989), only
a single SM treatment regimen was incorporated. Little is
known about whether SM could confer cardioprotection
when administrated to the myocardium before and during
ischemia.
Oxidative stress has been strongly implicated in myocar-
dial ischemia–reperfusion injury (IRI) (Das and Maulik
2006; Neuzil et al. 2005). Reactive oxygen species (ROS)
formation, primarily during reperfusion, was previously
thought responsible for IRI, but the importance of ROS for-
mation during ischemia has recently been emphasized. Re-
cent studies have demonstrated significantly increased
levels of 15-F2t-isoprostane (15-F2t-IsoP), a sensitive and re-
liable index of in vivo oxidative stress-induced lipid peroxi-
dation (Morrow and Roberts 1997), during the phase of
myocardial ischemia and early reperfusion (Ulus et al.
2003; Mehlhorn et al. 2003). We have recently shown that
the ischemic heart is a source of 15-F2t-IsoP generation
(Xia et al. 2003a, 2003b), and that 15-F2t-IsoP plays a caus-
ative role in mediating myocardial IRI in the isolated rat
hearts (Xia et al. 2005). Therefore, we hypothesized that
SM, when administrated before and during myocardial is-
chemia, should reduce 15-F2t-IsoP generation during ische-
mia and may confer similar or better cardioprotective
effects than its administration being initiated during reperfu-
sion in isolated ischemic reperfused rat hearts.
Materials and methods
Heart preparation
This study was approved by the institutional Committee
of Animal Care. The investigation conforms to the Guide
for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication
No. 85–23, revised 1996). Male Sprague–Dawley rats (280–
320 g) were anesthetized with pentobarbital (70 mg/kg, i.p.)
and heparinized with sodium heparin (1000 IU/kg, i.p.).
After median sternotomy, hearts were quickly excised and
immersed in ice-cold Krebs–Henseleit (KH) solution to stop
contractions. Hearts were gently squeezed to remove resid-
ual blood and prevent clot formation. They were then retro-
gradely perfused via the aorta in a nonworking Langendorff
preparation at a constant flow rate of 10 mL/min by using a
peristaltic pump. The perfusion flow rate (10 mL/min) was
based on the result of a pilot study showing that isolated
hearts beat well and remain hemodynamically stable for
120 min (the duration of the experiment) in our experimen-
tal set-up when perfused with KH without inducing ische-
mia. The perfusion fluid (pH 7.4, 37 8C) was KH solution
that contained (in mmol/L): NaCl, 118; NaHCO3, 24; KCl,
4.63; MgCl2, 1.2; CaCl2, 1.25; KH2PO4, 1.17; and glucose,
11. The perfusate was bubbled with a mixture of 95% O2
and 5% CO2. Temperatures of the perfusate solution and of
the chamber in which the hearts were held were maintained
at 37 8C by using a thermostatically controlled water-
circulating system.
Coronary perfusion pressure (CPP) was measured via a
side arm of the perfusion cannula connected to a pressure
transducer, as previously described (Xia et al. 2003b, 2004).
A latex water-filled balloon fixed to a pressure transducer
was inserted through the mitral valve into the left ventricle
for the determination of left ventricular (LV) developed
pressure (LVDP), which was calculated by subtracting end-
diastolic pressure (LVEDP) from LV peak systolic pressure
(LVSP). LVEDP was adjusted to approximately 5 mmHg
before the start of the experiment by adjusting the volume
in the intraventricular balloon. Exclusion criteria included
heart preparation times longer than 60 s and (or) LVSP
lower than 65 mmHg after 10 min of equilibration.
Experimental protocol
All hearts were initially equilibrated for 10 min (baseline,
BS). They were then randomly assigned to 1 of the 3 exper-
imental groups: ischemia–reperfusion untreated control (con-
trol, n = 7), SM pretreatment group (group SM1, n = 7), and
SM posttreatment group (group SM2, n = 7). After BS,
hearts in the SM1 group were perfused with KH containing
3 mg/mL of the purified aqueous extract of SM (1.5 g/mL,
Lot number 0405172, Chiatai Qingchunbao Pharmaceutical
Co., Ltd, Hangzhou, China) in the perfusate for 10 min be-
fore global ischemia (40 min) was induced by stopping per-
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fusion. The SM was provided as a concentrate that was
subsequently diluted into the perfusate at the concentration
(3 mg/mL) mentioned above. The SM concentration
(3 mg/mL) was chosen based on a recent study showing
that SM at 3 mg/mL attenuates anoxia and reoxygenation-
induced cellular injury in the isolated rat ventricular
cardiomyocytes (Cao et al. 2003). Hearts in the control
and the SM2 groups underwent an additional 10 min pe-
riod of equilibration before global ischemia was induced.
During ischemia, saline (control and SM2 groups) or SM
at 3 mg/mL in saline solution (group SM1) was perfused
through the aorta at 60 mL/min by using a mini-pump. KH
was perfused during 60 min of reperfusion in both the con-
trol and the SM1 groups. In the SM2 group, hearts were
perfused with SM at 3 mg/mL in KH during the first
15 min of reperfusion followed by perfusion with KH
alone for 45 min. Hearts were electrically paced at a rate
of 300 beats/min before and after, but not during, the is-
chemic period when hearts ceased to beat spontaneously.
Baseline effluent perfusate was sampled at BS (i.e.,
10 min after equilibration). Effluent samples during ische-
mia were collected during the first 30 min of ischemia
(isch) as described previously (Xia et al. 2003a). The choice
of this initial first 30 min interval, rather than 40 min, was
largely based on the factor that most similar studies used a
maximum of 30 min of global ischemia interval. So, it was
aimed to make a potential comparison easier. Also, effluent
was sampled for a duration of 0.5 min (which yielded
5 mL), respectively, at 0.5–1 (Re-1), 4.5–5 (Re-5), 29.5–30
(Re-30), and 59.5–60 (Re-60) min of reperfusion in the 3
experimental groups. Aliquots of the effluent samples were
immediately stored at –70 8C for later analysis for cardiac
specific creatine kinase (CK-MB) in all study groups. An-
other portion of the effluent sample was initially concen-
trated (see next section) and then stored at –70 8C for
analysis of endothelin-1 (ET-1) concentration. At the end of
the 60 min of reperfusion, 1% 2,3,5-triphenyltetrazolium
chloride (TTC) at 37 8C in buffer (0.1 mol phosphate/L buf-
fer adjusted to pH 7.4) was pumped into the heart at 1 mL
per min for 15 min until the epicardial surface became deep
red. The average TTC perfusion rate was 1.08 ± 0.04 mL/g
tissue. After the completion of TTC staining, the hearts were
weighed and then stored in 10% formaldehyde for later
analysis of myocardial infarct size.
Measurement of 15-F2t-isoprostane
Effluent free 15-F2t-IsoP levels were measured by using a
commercial enzyme-linked immunoassay kit (Cayman
Chemical, Ann Arbor, Mich.) as detailed previously (Xia et
al. 2003a, 2003b). The samples were coded and the investi-
gator responsible for 15-F2t-IsoP assays was blinded until
the completion of the assay.
Measurement of ET-1
Measurement of ET-1 concentrations in the coronary ef-
fluent was performed by using a commercially available hu-
man ET-1 enzyme immunometric assay kit (human ET-1
EIA kit 900–020, Assay Designs Inc., Ann Arbor, Mich.) as
detailed previously (Xia et al. 2005). The assay kit detects
ET-1 levels in biological fluids of human, bovine, canine,
murine, porcine, and rat samples (Wang and Wang 2004).
On the basis of pilot studies, ET-1 concentrations in
perfusate samples were often below the ET-1 sensitivity of
the assay (0.14 pg/mL). Therefore, effluent samples col-
lected during both ischemia and reperfusion were concen-
trated 4-fold by evaporation of solvent (i.e., KH) at room
temperature under a stream of dry nitrogen. ET-1 concentra-
tion was calculated as a quarter of the measured ET-1 level
in the concentrated sample. The accuracy of this approach
was confirmed by prior testing using known ET-1 standards
that yielded a recovery rate of 96.5% ± 1.2% (n = 5). The
assays plates were read at 450 nm, and the values of the un-
knowns were expressed as picograms of ET-1 per millilitre
of effluent.
Measurement of CK-MB
Measurement of CK-MB was performed by using a com-
mercially available enzyme immunoassay kit (Catalog num-
Fig. 1. Molecular structures of 4 bioactive ingredients purified from Salvia miltiorrhiza.
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ber BC-1121, BioCheck Inc., Foster City, Calif.) as de-
scribed previously (Xia et al. 2005). The values of the un-
knowns were expressed as nanograms of CK-MB per
millilitre of effluent.
Infarct size measurement
The measurement of infarct size was essentially identical
to that described by Qin et al. 2004 except for the method of
quantification. After the TTC reaction, the hearts were sec-
tioned transaxially and size of infarct was evaluated as per-
centage of sectional area of infarcted tissue to the sectional
area of the whole heart in 1-millimetre layers (5 layers, LG
scanner) as previously reported (Xia et al. 2005). Morpho-
metric measurements of infarct size were performed with a
LG scanner and 6.0 CE software. The histogram counts of
the red (viable) and white (infarcted) tissue were recorded.
The percentage infarction was calculated as white counts
divided by the sum of the red plus white counts.
Statistical analysis
All data are presented as means ± SEM. Cardiac variables
and chemical assay parameters were compared by two-way
ANOVA with Bonferroni correction (GraphPad Prism).
One-way repeated ANOVA and Tukey’s multiple compari-
son tests were applied for within-group comparison. p <
0.05 was considered statistically significant.
Results
Body and heart mass
The animals’ body mass (302.1 ± 5.5, 303.0 ± 4.7, and
300.5 ± 5.9 g, respectively, in the control, SM1, and SM2
groups) and heart mass (0.92 ± 0.03, 0.99 ± 0.05, and
0.91 ± 0.04 g, respectively, in the control, SM1, and SM2
groups) did not differ among groups (p > 0.1).
15-F2t-IsoP generation during ischemia–reperfusion
As shown in Fig. 2A, at BS, 15-F2t-IsoP values did not
differ among groups. During ischemia, 15-F2t-IsoP levels
were lower in the SM1 group than in the control (p < 0.05).
At Re-1, effluent 15-F2t-IsoP concentrations in the SM1
group tended to be lower than that in the control group, but
the difference did not reach statistical significance (p > 0.1).
During early reperfusion, level of effluent 15-F2t-IsoP con-
centrations decreased 74% in the SM2 group, 54% in the
control, and 38% in the SM1 group from Re-1 to Re-5. At
Re-5, levels of 15-F2t-IsoP in the SM2 group, but not in the
control and SM1 groups, decreased to baseline levels (p >
0.05 vs. BS). Effluent 15-F2t-IsoP returned to baseline levels
at Re-30 and onwards in all groups.
Effluent ET-1 release during ischemia and reperfusion
Baseline effluent ET-1 concentrations did not differ
among groups (p > 0.1, Fig. 2B). ET-1 increased during is-
chemia in the control groups (p < 0.05 vs. BS). It was about
28% lower in the SM1 group relative to the control, but this
difference did not reach statistical significance (p > 0.05,
Fig. 2B). ET-1 values at Re-1 in the control and SM2
groups were about 1.25-fold of their baseline levels, respec-
tively, but did not significantly differ from BS (p > 0.1 Re-1
vs. BS). Unexpectedly, ET-1 values at Re-1 and Re-5 in the
Fig. 2. Concentrations during myocardial ischemia–reperfusion of
(A) effluent 15-F2t-isoprostane, (B) endothelin-1 (ET-1), and
(C) CK-MB (cardiac specific creatine kinase). Baseline (BS) and
ischemia (isch) indicate 10 min after stabilization and 30 min dur-
ing global ischemia, respectively; Re-1, Re-5, Re-30, and Re-60 in-
dicate 1, 5, 30, and 60 min after reperfusion, respectively. Since the
levels of 15-F2t-isoprostane, ET-1, and CK-MB during ischemia
might reflect the slow perfusion rate and hence the ability to accu-
mulate high concentrations, their levels during ischemia and reper-
fusion were expressed as values (picograms, or nanograms, per
millilitre per minute) for convenient comparison. *, p < 0.05 vs.
BS; #, p < 0.05 vs. control.
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SM1 group were about 2.5-fold of its baseline value (p <
0.05 vs. BS), and were significantly higher than the corre-
sponding values in the control group (p < 0.05).
CK-MB release during ischemia–reperfusion
Baseline CK-MB release was detectable in this model and
did not differ among groups (Fig. 2B). During ischemia,
CK-MB levels were lower relative to the baseline values
the control and SM2 groups (p < 0.05 vs. BS), which may
indicate that the very low flow of saline solution given dur-
ing ischemia could only reach part of the myocardium adja-
cent to the coronary vasculature. CK-MB release during
ischemia was significantly lower in the SM1 group com-
pared with control (p < 0.05). Unexpectedly, significant in-
crease of CK-MB during early reperfusion at Re-1 was seen
in the SM1 group, but not in the control and SM2 groups.
CK-MB levels increased during reperfusion in the control
group, reached statistical significance at Re-30 compared
with baseline (p < 0.05 vs. BS), and remained increased at
Re-60. SM2 prevented the significant increased of CK-MB
seen in the control group during reperfusion. At Re-60, lev-
els of CK-MB in the SM2 group, but not in the SM1 group,
was lower than in that the control group (p < 0.05).
Contracture development during ischemia
The LVEDP increased progressively during ischemia in
all the 3 experimental groups and neither the magnitude of
LVEDP nor the peak contracture or time to peak contracture
significantly differ among them (data not shown). However,
time to the onset of ischemic contracture, defined as eleva-
tion of LVEDP ‡ 2.5 mmHg above baseline value, was sig-
nificantly longer in the SM1 group (23.5 ± 1.2 min) than in
the control group (18.0 ± 1.6 min) and SM2 group (17.5 ±
1.7 min) (p < 0.05).
Fig. 3. Variations of left ventricular end-diastolic pressure
(LVEDP) reflecting myocardial stiffness during reperfusion (A),
and recovery of left ventricular developed pressure (LVDP) reflect-
ing effective myocardial contractility during reperfusion (B). Base-
line (BS) and preischemia values indicate 10 min after stabilization
and the time immediately before ischemia, respectively; Re-10, Re-
30, and Re-60 indicate 10, 30, and 60 min after reperfusion, re-
spectively. For both A and B, *, p < 0.05 vs. BS; #, p < 0.05 vs.
control.
Fig. 4. Variations of coronary perfusion pressure (CPP) before
ischemia and during postischemic reperfusion. Baseline (BS) and
preischemic values indicate 10 min after stabilization and the time
immediately before ischemia, respectively; Re-10, Re-30, and Re-
60 indicate 10, 30, and 60 min after reperfusion, respectively.
*, p < 0.05 vs. BS; #, p < 0.05 vs. control.
Fig. 5. Myocardial infarct size following 40 min of global ischemia
and 60 min of reperfusion. SM1 and SM2 indicate Salvia miltior-
rhia (SM) treatment regimens 1 and 2, respectively; *, p < 0.05 vs.
control.
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Functional response to ischemia–reperfusion
During reperfusion, LVEDP in all the groups was signifi-
cantly higher than the corresponding baseline values
(Fig. 3A), which tended to decrease toward the end of reper-
fusion. SM2, but not SM1, significantly attenuated the ele-
vation of LVEDP at Re-30 and Re-60 compared with
control group (p < 0.05).
The LVDP in the control group recovered to a maximum
of 87% ± 12% of its baseline value at Re-30 (p > 0.05 vs.
BS, Fig. 3B) and decreased thereafter. The LVDP in the
SM1 group was lower than that in the control group at Re-
10 (p < 0.05) and gradually increased thereafter. The LVDP
in the SM2 group recovered to 90% ± 10% of its baseline
value at Re-30 (p > 0.05 vs. BS, Fig. 3B) and maintained at
this level thereafter. At Re-60, LVDP in the SM2 group, but
not in the SM1 group, was significantly higher than that in
the control group.
Coronary perfusion pressure
Coronary perfusion pressure (CPP) did not increase sig-
nificantly until after 60 min of reperfusion in the untreated
control group (p < 0.05 vs. BS, Fig. 4). CPP in the SM1
group rapidly increased during early reperfusion and was
higher than that in the control group at Re-10. It remained
elevated throughout reperfusion in the SM1 group (p < 0.05
vs. baseline and control). In contrast, SM2 prevented the
significant increase of CPP seen in the control group.
Myocardial infarct size
As shown in Fig. 5, myocardial infarct size in the un-
treated group was 25.5% ± 2.1% (n = 7, range 21.5%–
32.0%). This infarct size is relatively smaller than that seen
in ischemic–reperfused untreated hearts (n = 3, 46.5% ±
5.0%, unpublished data) previously studied under the same
experimental conditions (i.e., 40 min global ischemia fol-
lowed by 60 min reperfusion) except that no saline solution
was infused during the global ischemia. This is suggestive
that the small volumes of saline infusion during ischemia in
the current study may serve to wash out some toxic substan-
ces produced during ischemia, therefore attenuating myocar-
dial injury. At 60 min postischemic reperfusion, the
myocardial infarct size in the SM2 group (19.8% ± 1.6%),
but not in the SM1 group (22.4% ± 2.4%) was significantly
smaller than that in the control group (p < 0.05, Fig. 5).
Discussion
A novel, but somewhat surprising, finding of the current
study is that SM administration before and during myocar-
dial ischemia attenuated oxidative stress and myocardial
cellular damage during ischemia, but followed by more se-
vere cellular damage during the early phase of reperfusion
in the isolated ischemic–reperfused rat hearts as compared
with untreated control hearts. The 15-F2t-IsoP formation and
CK-MB release during ischemia in the SM1 group were
lower than that in the control group accompanied with sig-
nificantly delayed ischemic contracture onset time, sugges-
tive of a cardioprotective effect of the SM1 treatment
regimen during ischemia. However, the SM1 treatment regi-
men resulted in more severe myocardial cellular damage
during early reperfusion manifested as significant increase
of CK-MB release at Re-1 relative to control. Increased
myocardial cellular damage seen in the SM1 group during
early reperfusion might be attributable, in part, to the signif-
icant increase of CPP during early reperfusion, which might
be either a cause and (or) a consequence of coronary artery
endothelial cell damage.
A study has shown that coronary vascular endothelial cell
injury occurs prior to cardiomyocyte injury in the isolated
rat hearts subjected to 35 min of regional ischemia followed
by up to 120 min of reperfusion (Scarabelli et al. 2001).
Also, impairment of coronary vasodilation (microvascular
‘‘stunning’’) may persist for hours after a brief (15 min) re-
versible ischemia (Bolli et al. 1990). Hence, in the current
study, the study agent SM diluted in saline was given at a
very low infusion rate (60 mL/min) in the SM1 group during
global ischemia, attempting to ameliorate vascular injury
during and postischemia and subsequently attenuating myo-
cardial IRI. This is based on the assumption that an agent
perfused at this low infusion rate is unlikely to be able to
reach the myocardium in significant amount, but rather
mainly interacts with the vascular endothelium and as such
may confer beneficial effects during myocardial ischemia–
reperfusion in this model (Xia et al. 2004). The relatively
lower CK-MB levels in the effluent during ischemia com-
pared with baseline in the control group (Fig. 2) might serve
as an indirect evidence that saline solution perfused at a
very low flow rate (60 mL/min) could only reach part of the
myocardium adjacent to the coronary vasculature. It should
be noted, however, this model does not exactly simulate the
clinical scenario during cardiac surgery in which the agents
are given as addictives to the cardioplegia. Therefore, cau-
tion has to be exercised when interpreting the results in clin-
ical settings. Nevertheless, the current approach (infusing
the agent alone at a very low rate during ischemia) avoided
confounding the potential vascular protective effects of the
cardioplegia.
The mechanism responsible for the increase of CPP
during early reperfusion in the SM1 group is not very clear.
Since we used constant flow rate perfusion in the current
study, the increase of CPP should reflect the increased
release or activity of vascular constrictive substances or
decreased release or activity of vasodilators. Therefore, the
dramatic increase of ET-1 during early reperfusion seen in
the SM1 group should be responsible, at least in part, for
the increase of CPP during early reperfusion. Given the anti-
oxidant nature of SM (Cao et al. 2003), it seems difficult to
understand that antioxidant therapy before and during
myocardial ischemia should lead to the increase of ET-1
during early reperfusion. Whereas burst production of reac-
tive oxygen species occurs during early reperfusion (Bolli et
al. 1989), significant superoxide generation occurs in the
cardiomyocyte during ischemia before reperfusion (Becker
et al. 1999). We suspect that the generation of small amount
of superoxide during early phase of ischemia may have
exerted an ‘‘ischemic preconditioning (IPC)’’-like protective
effect. IPC refers to the ability of short periods of ischemia
to render the myocardium more resistant to a subsequent
ischemic insult, a phenomenon first identified by Murry and
colleagues (Murry et al. 1986). The effects of IPC rely on the
generation of small amount of superoxide to render an acute
and delayed cardioprotection (Kevin et al. 2005; Pagliaro et
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al. 2001). The superoxide generated during preconditioning
may prepare the heart to produce increased amount of en-
dogenous antioxidant enzymes such as superoxide dismu-
tase, which may serve to reduce the burst production of
reactive oxygen species during reperfusion and attenuate
postischemic myocardial dysfunction (Bolli et al. 1989).
On the other hand, superoxide has been shown to inhibit
endothelin-converting enzyme, the enzyme that cleaves big
ET-1 into ET-1, and decrease ET-1 formation in the cul-
tured bovine aortic endothelial cells (Lopez-Ongil et al.
2000). Therefore, the SM1 treatment regimen may have
blocked the potential beneficial effects of superoxide gen-
erated before and especially during early phase of ische-
mia, which may have resulted in increased endothelin-
converting enzyme activity, leading to the subsequent burst
increase of ET-1 release during early reperfusion. This no-
tion is indirectly supported by the most recent finding of
Duda et al. (2007), which shows that IPC prevents the
burst increase of ET-1 during reperfusion in the isolated
ischemic–reperfused guinea-pig hearts. However, further
study is needed to verify our hypothesis that superoxide
generated during early phase of ischemia may confer bene-
ficial effects.
Another interesting finding of the current study is that ad-
ministration of SM solely during the early phase of reperfu-
sion (SM2 group) prevented the increase of CK-MB and
CPP during reperfusion seen in the control group, and ended
up with accelerated postischemic myocardial functional re-
covery (Fig. 3B) and reduced myocardial infarct size
(Fig. 5). The results are consistent with the notion that the
first minutes of reperfusion is a window of opportunity for
cardioprotection (Piper et al. 2004). CK-MB is a relatively
more cardiac-specific isoenzyme of the creatine kinase fam-
ily. However, it also exists in other tissues like the skeletal
muscle and elevates when skeletal muscle injury occurs. The
isolated heart preparation ensures that CK-MB elevation can
be served as a specific marker of myocardial cellular dam-
age. Similar to our previous study (Xia et al. 2005) and
studies of others (Calabresi et al. 2003; Chocron et al.
1996), CK-MB concentration in the effluent perfusate was
increased during postischemic reperfusion in the isolated rat
hearts (Fig. 2C). To our knowledge, our study is the first to
report that SM, when administrated solely during early re-
perfusion, reduces cardiac CK-MB release in the isolated
ischemic-reperfused hearts, confirming its cardioprotective
effects. It is worth noting that SM2 treatment led to faster
reduction of 15-F2t-IsoP concentration in the perfusate dur-
ing early reperfusion. At Re-5, levels of 15-F2t-IsoP in the
SM2 group, but not in the control or SM1 group, decreased
to a level comparable with the baseline values (Fig. 2), indi-
cative of increased antioxidant potential in the SM2 group.
Hence, enhancement of antioxidant potential during early re-
perfusion may represent a mechanism whereby SM2 facili-
tates postischemic myocardial functional recovery and
reduced myocardial infarction. In addition to its antioxidant
capacity, aqueous extracts of SM have been shown to dilate
coronary artery by inhibition of calcium channels (Lam et
al. 2007). The gradual increase of CPP during reperfusion
seen in the control group suggests a gradual vascular closure
in the isolated heart perfused under nonphysiological perfu-
sion conditions (i.e., nonblood perfusion), which renders part
of the myocardium to a hypoxic condition, resulting in in-
creased CK-MB release during reperfusion. Therefore, the
cardioprotection seen in the SM2 group should be attribut-
able, in part, to its coronary dilatory effects evidenced by
significantly lower CPP at Re-60 compared with the control
and SM1 group. On the contrary, the cardioprotective effects
of SM1 manifested during ischemia (evidenced by reduced
CK-MB release and delayed onset of ischemic contracture)
may have been counteracted by the subsequent increase of
ET-1 and CPP during reperfusion that caused increased pos-
tischemic myocardial cellular damage. This may explain
why SM1 confers a neutral cardioprotective effect in terms
of postischemic functional recovery despite the reduction of
myocardial damage during ischemia.
In summary, we have shown that SM application before
and during myocardial ischemia postponed, but did not sig-
nificantly attenuate postischemic myocardial injury. The
mechanism for this phenomenon is unclear and merits fur-
ther studies. Application of SM during reperfusion reduced
15-F2t-IsoP production during early reperfusion that led to
optimal postischemic myocardial functional recovery and re-
duced myocardial infarct size. We conclude that
S. miltiorrhiza could be beneficial in the treatment of myo-
cardial ischemic injury and the timing of administration
seems important. Results from this study may shed light on
the mechanisms responsible for the conflict results of agents
with antioxidant property such as the anesthetic propofol,
which has been reported to be either beneficial (Xia et al.
2003a, 2003b; Kokita and Hara 1996) or not cardioprotec-
tive (Ross et al. 1998; Ebel et al. 1999) in various myocar-
dial ischemia–reperfusion models.
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